Glecaprevir

  • CAT Number: I006612
  • CAS Number: 1365970-03-1
  • Molecular Formula: C38H46F4N6O9S
  • Molecular Weight: 838.87
  • Purity: ≥95%
Inquiry Now

Glecaprevir(CAT: I006612) is a prescription medication used for the treatment of chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral agent that works by inhibiting the NS3/4A protease, an enzyme that is essential for the replication of HCV. Glecaprevir is typically used in combination with another direct-acting antiviral agent, pibrentasvir, as a fixed-dose combination medication.

Catalog Number I006612
CAS Number 1365970-03-1
Synonyms

ABT-493; A-1282576; ABT493; A1282576; ABT 493; A 1282576;(33R,35S,91R,92R,5S,E)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-14,14-difluoro-4,7-dioxo-2,8,10-trioxa-6-aza-1(2,3)-quinoxalina-3(3,

Molecular Formula

C38H46F4N6O9S

Purity 95%
Target NS 3/4A inhibitor
Solubility Soluble in DMSO
Storage 0 - 4°C for short term or -20 °C for long term
InChI InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19
InChIKey MLSQGNCUYAMAHD-ITNVBOSISA-N
SMILES O=C([C@H]1N(C2)C([C@H](C(C)(C)C)NC(O[C@@](CCC3)([H])[C@]3([H])OC/C=C/C(F)(F)C4=NC5=CC=CC=C5N=C4O[C@]2([H])C1)=O)=O)N[C@@]6(C(NS(=O)(C7(C)CC7)=O)=O)[C@H](C(F)F)C6
Reference

<br />
1:Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Scott Overcash J, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ.J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211-8. doi: 10.1016/j.jhep.2017.03.039. [Epub ahead of print] PMID: 28412293 <br />
2:Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ.Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081. [Epub ahead of print] PMID: 28128852

Request a Quote